Introduction {#sec1}
============

Peripheral arterial disease (PAD), is characterized by the formation of atherosclerotic plaques that limit blood flow to the legs, and affects approximately 5% of the general population, with the prevalence increasing to 15--20% in persons over 70 years [@ref1]. PAD is commonly divided in four clinical stages [@ref1]. In the early stage of PAD, the patients experience no symptoms. This stage is defined as Stage I (asymptomatic PAD) according to the Fontaine classification system. By far, the most common clinical manifestation of symptomatic PAD is claudication (*i.e.*, Fontaine Stage II), a severe functional limitation identified as gait dysfunction and walking-induced leg muscle pain relieved by rest. In its less common advanced stages, symptomatic PAD becomes limb-threatening and patients have foot pain at rest (*i.e.*, Fontaine Stage III) or more commonly non-healing ulcers and necrosis/gangrene (*i.e.*, Fontaine Stage IV).

Previous studies, have documented a myopathy in the PAD muscle that is characterized by defective mitochondrial bioenergetics, oxidative stress and abnormal skeletal muscle histomorphology and function ([Fig. 1](#f0005){ref-type="fig"}) [@ref2; @ref3; @ref4; @ref5; @ref6; @ref7; @ref8; @ref9; @ref10]. Our group has previously shown the central importance of oxidative damage in the pathophysiology of PAD myopathy demonstrating a significant increase in oxidative damage in PAD muscle and its myofibers compared to controls. At the myofiber level, we found that the levels of oxidative damage in PAD increase as the hemodynamics of the blood flow to the leg worsen and as the disease advances from Fontaine stage II to stage III and stage IV [@ref10]. Furthermore, we have shown that oxidative damage is not a homogeneously diffuse process but varies from myofiber to myofiber in the affected muscles and that the more atrophic myofibers have higher levels of oxidative damage [@ref10]. Mechanistically, it is not known whether oxidative damage in PAD limbs is selective for a specific subpopulation of myofibers and whether certain characteristics of myofibers may make them more sensitive or prone to oxidative damage.

The myofibers of human muscles belong to three classes differentiated on the basis of myosin heavy chain phenotype and differing on the basis of their speed of contraction and predominant type of energy metabolism [@ref11]. Type I (slow twitch) fibers are characterized by higher mitochondrial content and more oxidative energy metabolism. Type II (fast twitch) fibers have a lower mitochondrial content and greater dependence on glycolysis. Mixed (Type I/II) fibers are intermediate in mitochondrial content and energy metabolism and are transitioning between Type I and Type II fibers. Other groups have previously evaluated the different types of myofibers in the gastrocnemius of ischemic limbs of PAD patients. Their findings have demonstrated a tendency for selective loss of Type II fibers relative to Type I fibers and a significant decrease in the average cross sectional area of individual Type II fibers [@ref3; @ref9]. Considering the possibility that the finding of selective loss of Type II fibers is related to increased oxidative damage in this type of fibers we hypothesized that increased oxidative damage in ischemic muscle of PAD patients is myofiber type selective and correlates with reduced myofiber size. We also hypothesized that oxidative stress and its myofiber type selectivity, will increase with advancing disease stage from stage II to stage IV.

Materials and methods {#sec2}
=====================

Human subjects {#sec2.1}
--------------

The experimental protocol was approved by the Institutional Review Board, of the VA, Nebraska-Western Iowa and University of Nebraska Medical Centers, and all subjects gave informed consent. We recruited 53 patients evaluated for symptomatic PAD ([Table 1](#t0005){ref-type="table"}). Twenty eight patients presented with claudication (PAD-II; Fontaine Stage II) and twenty five presented with tissue loss (PAD-IV; Fontaine Stage IV). For every patient, the diagnosis of PAD was established on the basis of medical history, physical examination, significantly decreased ankle-brachial index (ABI) and computerized or standard arteriography. We recruited twenty five patients with normal blood flow to their lower limbs, undergoing lower extremity operations for indications other than PAD ([Table 1](#t0005){ref-type="table"}). These patients had no history of PAD symptoms, and all had normal lower extremity pulses at examination. All controls were selected to have normal ABIs at rest and after stress and all led sedentary lifestyles.

Muscle biopsy {#sec2.2}
-------------

Gastrocnemius samples were obtained from the anteromedial aspect of the muscle belly, 10 cm distal to the tibial tuberosity. All biopsies were obtained with a 6 mm Bergstrom needle. The samples were placed immediately into cold methacarn. After 48 h in methacarn, the specimens were transferred to cold ethanol:H~2~O (50:50 v/v) and subsequently embedded in paraffin.

Quantitative fluorescence microscopy {#sec2.3}
------------------------------------

Paraffin-embedded biopsies sectioned at 4 µm were labeled with three fluorescent reagents for identifying Type I and Type II fibers and for quantification of ROS-induced oxidative damage in myofibers. Slide specimens of gastrocnemius biopsies were deparaffinized, rehydrated, and treated with 100 mM citrate buffer (pH 6.0) at 90 °C for 15 min. For measurement of protein carbonyls [@ref10; @ref12], endogenous biotin was blocked and then carbonyl groups were biotinylated by treatment of slide specimens, first with 5 mM EZ-Link Hydrazide Biocytin (Thermo Scientific-Pierce Protein Research Products, Rockford, IL; \#28020) in 100 mM 2-morpholinoethane sulfonic acid buffer (pH 6.5) for 1 h and then with cold 15 mM cyanoborohydride in Dulbecco's PBS for 1 h. For labeling of Type I and Type II fibers, specimens were blocked with 10% goat serum and treated with a mixture of mouse monoclonal antibody specific for Type I MHC (1 µg/mL; Sigma-Aldrich, St. Louis, MO) and a rabbit polyclonal antibody specific for Type II MHC (1 µg/mL; Abcam, Cambridge, MA). Control slides were treated with a mixture of mouse (1 µg/mL; eBioscience, San Diego, CA) and rabbit IgG (1 µg/mL; eBioscience, San Diego, CA). After overnight incubation for 12 h at 4 °C, the slides were labeled for 1 h, at room temperature, with a mixture of Alexa Fluor^®^ 488 conjugated streptavidin (10 µg/mL; Life Technologies-Molecular Probes, Grand Island, NY), an Alexa Fluor^®^ 555 conjugated goat anti-mouse IgG (10 µg/mL; Life Technologies-Molecular Probes) and an Alexa Fluor^®^ 647 conjugated goat anti-rabbit IgG (10 µg/mL; Life Technologies-Molecular Probes). The conditions for all the fluorescent labels were adjusted to achieve maximal fluorescence signals required for quantitative analysis [@ref13; @ref14]. Subsequently, myofiber sarcolemmas were labeled for 1 h with Alexa Fluor^®^ 350 conjugated Wheat Germ Agglutinin (10 µg/mL; Life Technologies-Molecular Probes). The specimens were mounted in ProLong Gold^®^ anti-fade medium with DAPI (Life Technologies-Molecular Probes). Duplicate slides of each biopsy specimen were analyzed. Isotype control slides exhibited no detectable fluorescence labeling.

Image acquisition and analysis {#sec2.4}
------------------------------

Gray-scale (12-bit) fluorescence images (1344×1044) were captured with a widefield, epifluorescence microscope (Leica DMRXA2; North Central Instruments, Plymouth, MN) (10× objective; 0.5128 µm/pixel), a B/W CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater, NJ) and HCImage Hamamatsu software (64-bit v.4.1; Hamamatsu Photonics, Bridgewater, NJ). An acquisition matrix was programed into the HCImage software to cover the whole muscle specimen area, acquiring a range of 60--150 microscopic frames per specimen yielding images of 80,640×62,640--201,600×156,600 pixels. At each location, images were collected in fluorescence channels corresponding to each fluorophore; (1) excitation at 350 nm and emission at 460 nm (Alexa Fluor 350), (2) excitation 480 nm and emission at 535 nm (Alexa Fluor 488), (3) excitation 555 nm and emission at 565 nm (Alexa Fluor 555) and (4) excitation 647 nm and emission at 670 nm (Alexa Fluor 647). The frames corresponding to each fluorophore were montaged in one large image to represent the given (whole) specimen. Image segmentation was done with a custom made Matlab algorithm (R2012a, Mathworks Inc., Natic, MA), using thresholding, edge detection, regionprops and a set of heuristics [@ref2]. Labeled sarcolemma acquired at 460 nm provided a binary image that served as an outline for each myofiber was imposed on the images of Type I fibers acquired at 565 nm ([Fig. 2](#f0010){ref-type="fig"}) and Type II fibers acquired at 670 nm ([Fig. 2](#f0010){ref-type="fig"}) fibers. Then, images of Type I and II fibers were extracted separately as well as those labeled with both Type I/II identified as mixed fibers ([Fig. 2](#f0010){ref-type="fig"}). Subsequently, images of carbonyl groups acquired at 535 nm were extracted for each myofiber Types I, II and I/II ([Fig. 2](#f0010){ref-type="fig"}). Measurements of myofiber size, including cross-sectional area, equivalent diameter and perimeter, and myofiber shape, including roundness and solidity, were calculated for each myofiber classified as Types I, II, I/II. The methods describing how these parameters were measured have been described in detail [@ref2]. Briefly, we calculated (1) myoﬁber cross-sectional area, as the number of pixels enclosed within a segmented myoﬁber, (2) myoﬁber perimeter, as the number of pixels on the boundary of the myoﬁber, (3) equivalent diameter, as the diameter of a circle that has the same area as the segmented myoﬁber region, (4) roundness, as the equivalent diameter x *π* divided by the perimeter of the segmented region, and (5) solidity, defined as the myofiber cross-sectional area divided by the area of a ﬁtted convex hull. A ﬁtted convex hull is the smallest convex polygon that can encompass the myoﬁber.

Statistical analyzes {#sec2.5}
--------------------

Baseline characteristics between PAD patients and control subjects were compared using chi-square or Fischer's exact tests for categorical variables and independent *t*-tests for continuous variables. A one-way analysis of covariance was used to identify differences between PAD and control groups for all myofiber types adjusting for the effects of smoking status, followed by *post-hoc* analyzes with Bonferroni correction. A one-factor repeated measures design was used to identify differences among fiber types within each group, followed by *post-hoc* analyzes with Bonferroni correction. Partial bivariate correlations were used to correlate oxidative damage with myofiber morphology parameters adjusting for the effect of smoking status. All analyzes were performed using SAS statistical software version 9.3 (SAS Institute Inc., Cary, North Carolina).

Results {#sec3}
=======

Subject demographics {#sec3.1}
--------------------

The baseline demographic and clinical characteristics are presented in [Table 1](#t0005){ref-type="table"}. As expected, PAD patients had significantly lower ABI values than control subjects (PAD 0.40±0.04 *vs.* controls: 1.08±0.02, *p*\<0.001). Smoking status was significantly higher in PAD patients compared to controls (*χ*^2^=10.9, *p*=0.001). No other differences were found among the PAD patients and control subjects.

Gastrocnemius specimens of PAD patients exhibited increased oxidative damage, reduced myofiber size and altered morphology {#sec3.2}
--------------------------------------------------------------------------------------------------------------------------

Myofibers of PAD patients (*n*=53) exhibited a 25% greater burden of carbonyl groups (oxidative damage) (all myofiber types combined) compared to myofibers of control patients (*n*=25; [Fig. 3](#f0015){ref-type="fig"}). Furthermore, carbonyl content was significantly greater for each individual fiber Type in the PAD patients compared to controls ([Table 2](#t0010){ref-type="table"}). In addition, almost every parameter of size and shape was significantly different in the myofibers (all myofiber types combined) of PAD patients compared to controls. This was also true for each individual Type of myofiber in PAD gastrocnemius compared to controls ([Table 2](#t0010){ref-type="table"}).

Increased oxidative damage correlated inversely with the observed abnormalities in the size and shape of PAD myofibers, suggesting that increased oxidative damage produced loss of structural integrity of PAD myofibers. Specifically, the carbonyl content of PAD myofibers (all myofiber types combined) was negatively associated with myofiber cross-sectional area (*r*=−0.401, *p*\<0.001), equivalent diameter (*r*=−0.346, *p*=0.002), perimeter (*r*=−0.314, *p*=0.005) and solidity (*r*=−0.305, *p*=0.007).

Type II and Type I/II (mixed) myofibers exhibited greater oxidative damage compared to Type I myofibers in PAD gastrocnemius {#sec3.3}
----------------------------------------------------------------------------------------------------------------------------

The variability of oxidative damage among myofibers in individual PAD and control specimens suggested the possibility of selective damage to the Type II fibers, previously shown to be preferentially affected in PAD muscle [@ref3]. We found that oxidative damage was higher in Type II and Type I/II fibers compared to Type I fibers in PAD patients. Furthermore, Type II fibers demonstrated 34% increase (highest increase among the different myofiber types) of carbonyl content compared to control ([Table 2](#t0010){ref-type="table"}). In PAD gastrocnemius, Type II and Type I/II fibers demonstrated greater damage compared to Type I (Type I *vs.* Type II, *p*\<0.001; Type I *vs.* Type I/II, *p*\<0.001). In the control gastrocnemius no differences were observed among the fiber types.

Type II and Type I/II (mixed) myofibers exhibited a greater reduction in size and alteration in shape compared to Type I myofibers in PAD gastrocnemius {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Similar to the oxidative damage results, the parameters of myofiber size including cross-sectional area, equivalent diameter and perimeter and myofiber shape including solidity and roundness were significantly reduced in the PAD gastrocnemius myofibers compared to controls for all three myofiber types ([Table 2](#t0010){ref-type="table"}).

Furthermore, in comparison to Type I myofibers, Type II fibers exhibited a greater decrease in cross-sectional area (*p*\<0.001), equivalent diameter (*p*\<0.001), perimeter (*p*\<0.001), solidity (*p*=0.020) and roundness (*p*=0.001) ([Table 3](#t0015){ref-type="table"}). Type I/II compared to Type I fibers exhibited decreased cross-sectional area (*p*=0.002), equivalent diameter (*p*\<0.001), perimeter (*p*=0.007), and roundness (*p*=0.019) ([Table 3](#t0015){ref-type="table"}). No differences were observed between Type II and Type I/II fibers.

Oxidative damage increased in association with reduced myofiber size and altered myofiber morphometrics as the disease progressed {#sec3.5}
---------------------------------------------------------------------------------------------------------------------------------

To evaluate the hypothesis that oxidative damage and myofiber size and shape are associated with the patient's stage of disease, we separated the PAD group ([Table 1](#t0005){ref-type="table"}) into PAD Fontaine Stage II (Stage II, *n*=28 patients) and PAD Fontaine Stage IV (Stage IV, *n*=25 patients) and evaluated differences in myofiber oxidative damage and morphometrics in the gastrocnemius of the two groups ([Table 3](#t0015){ref-type="table"}). Carbonyl content for all three fiber types was significantly increased in the PAD-IV patients compared to PAD-II patients ([Table 3](#t0015){ref-type="table"}). Similarly, myofiber cross-sectional area, equivalent diameter, perimeter, solidity and roundness were significantly reduced in PAD-IV patients compared to PAD-II patients ([Table 3](#t0015){ref-type="table"}). Among the myofibers of PAD-II patients, Type II fibers exhibited the most damage for all the parameters (*p* \< 0.01) with the exception of solidity and roundness compared to Type I fibers. In contrast, in PAD-IV myofibers both Type II and Type I/II fibers were equally damaged compared to Type I fibers.

Type II fibers were preferentially lost, in PAD {#sec3.6}
-----------------------------------------------

Frequency analysis of Type I, Type II and Type I/II myofibers provided further support for our findings of selective oxidative damage to Type II myofibers with a shift in the ratio of Type II to Type I myofibers in PAD ([Fig. 4](#f0020){ref-type="fig"}). In the gastrocnemius of the control group, the proportion of Type I, Type II and transitional Type I/II fibers was 48%, 51% and 1%, respectively. In the gastrocnemius of PAD-II patients, the proportion of Type I, Type II and transitional Type I/II fibers was 56%, 42% and 2%, respectively. In PAD-IV patients the proportion of Type I, Type II and transitional Type I/II fibers was 56%, 38% and 6%, respectively. The data are consistent with a shift from Type II myofibers to Type I for both PAD groups (*p*\<0.01) and indicate that with advancing disease there is a shift from Type II to Type I, transitioning through Type I/II.

Discussion {#sec4}
==========

Our study of gastrocnemius muscle from patients with PAD demonstrates increased oxidative damage in all fiber types in the PAD patients compared to control subjects. Increased oxidative damage was associated with reduced size (decrease in cross-sectional area, equivalent diameter and perimeter) and abnormal shape (less polygonal and more irregular) of myofibers across all fiber types. Reports of preferential loss of Type II fibers in PAD skeletal muscle [@ref3; @ref9; @ref15], led us to hypothesize that this loss is related to increased oxidative damage in Type II myofibers. In support of this hypothesis, our present study revealed greater oxidative damage in Type II compared to Type I myofibers in association with smaller fiber size and more pronounced abnormalities in fiber shape, changes that indicate significant damage to the myofibrillar, cytoskeletal and membranous components of the myofiber [@ref16; @ref17]. We also observed increased frequency, higher levels of oxidative damage and markedly altered size and shape of hybrid fibers (Type I/II) in PAD compared to control gastrocnemius. Hybrid fibers represent transitions between Type II and Type I fibers and become more numerous whenever fiber type shifts occur [@ref18]. Therefore, the hybrid myofibers in PAD muscle are probably oxidatively damaged Type II myofibers transitioning to the Type I phenotype hence their higher carbonyl content, smaller size and increased frequency, with disease progression. In general, we found that for all myofiber types, oxidative damage, cross-sectional area and shape abnormalities are directly related to progression from claudication to tissue loss (critical limb ischemia). Taken together, our data demonstrate that in PAD, chronic ischemia and ischemia-reperfusion operate to increase oxidative damage that produces severe myopathic changes in the gastrocnemius muscle. The myopathy of PAD is characterized by preferential oxidative damage and degeneration of the fast twitch (Type II) myofibers and a fast (Type II) to slow (Type I) myofiber type shift represented by a decrease of Type II fibers and a concomitant increase of the Type I and mixed Type I/II fibers.

Muscle wasting is present in a variety of clinical conditions including disuse, denervation, microgravity, heart failure, chronic obstructive pulmonary disease, cachexia of cancer and sepsis and sarcopenia of aging [@ref18; @ref19]. In most of these conditions reduced myofiber size occurs preferentially in certain fiber types and/or is accompanied by shifts in the fiber type profile. Preferential reduction in the size of Type I fibers and a slow to fast myofiber shift is usually seen in the leg muscles of patients after disuse, denervation injury (nerve or spinal cord trauma), exposure to microgravity (space travel), heart failure or chronic obstructive pulmonary disease [@ref18; @ref19]. In contrast, a preferential reduction in the size of Type II fibers and a fast to slow shift is usually seen in the leg muscles of patients suffering from cancer, dietary insufficiency, sepsis and sarcopenia of aging [@ref18; @ref19]. Our findings suggest that the myopathy of PAD shares some similarities with the muscle wasting seen in diseases of nutrient-deficiency like cancer, sepsis and aging. This is potentially important for several reasons. First, it points to possible analogies between the mechanisms operating to produce the myopathy of PAD and those of cancer and aging [@ref20; @ref21; @ref22]. Such mechanisms may (among others explored below) include a structural and dynamic malfunction of the vascular system in these diseases [@ref23; @ref24]. Second, it suggests that although decreased functional performance and activity is one of the prominent manifestations of PAD, it is unlikely that a disuse type of muscle wasting (usually seen with limb inactivity/immobilization or nerve injury) is a dominant contributor to the myopathy of PAD.

The mechanism of selective loss of Type II myofibers in PAD has not yet been established. Our results suggest that this loss is a consequence of selective oxidative damage to the Type II fibers ([Fig. 4](#f0020){ref-type="fig"}). To date, remarkably few investigations have been concerned with the biochemical basis for selective oxidative damage to and reduced size of Type II fibers in disease and aging. In a recent study of rat skeletal muscle, Anderson and Neufer [@ref25] found a significantly higher mitochondrial free radical leak, expressed as the ratio of H~2~O~2~ production to O~2~ utilization, in white (predominantly Type IIB fibers) and red (predominantly Type IIA fibers) gastrocnemius, compared to soleus muscle (predominantly Type I fibers). They concluded that Type II fibers were potentiated uniquely to generation of H~2~O~2~. In a related study, Stefanyk et al. [@ref26] identified a potential mechanism that could explain our present findings of fiber type selective oxidative damage and altered morphometrics. While studying fatty acid composition of mitochondrial membranes from soleus, red gastrocnemius and plantaris (predominantly Type IIB fibers) muscle of the rat, these investigators found a significantly higher mole fraction of saturated fatty acids and a lower mole fraction of ω6 polyunsaturated fatty acids in the soleus, compared to red gastrocnemius and plantaris. The unsaturation index and, therefore, the lipid peroxidation index were lower in the soleus. Similarly, cardiolipin of the mitochondrial membranes of the soleus contained more saturated fatty acids and less polyunsaturated fatty acids than the mitochondrial membranes of red gastrocnemius and plantaris, producing 20--30% lower unsaturation and lipid peroxidation indices in the soleus. Taken together, these findings are consistent with our present findings of increased sensitivity of II fibers to oxidative damage, leading to their preferential loss and a shift towards Type I myofibers in PAD.

A substantial body of work has explored the subject of muscle wasting and its relation to different acute or chronic diseases and aging and excellent reviews on the subject have been recently published [@ref18; @ref27]. At the molecular level certain common mechanisms appear to be related to preferential reduction in the size and frequency of Type II fibers in the nutrient-related (cancer, dietary insufficiency, sepsis and aging) type of muscle wasting. These mechanisms involve abnormal activation of the proteolytic pathways including the proteasomal and lysosomal pathways [@ref28]. The best explored signaling networks involved in the process are related to the Forkhead box O family, the transforming growth factor beta family, and nuclear factor-kappaB [@ref29; @ref30; @ref31; @ref32; @ref33]. Type II myofibers are more sensitive to these mechanisms and a significant factor contributing the resistance of Type I fibers is the activity of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, a well described transcriptional coactivator required for mitochondrial biogenesis, protection from proteolysis and maintenance of the slow twitch, oxidative fiber phenotype of Type I myofibers [@ref34; @ref35; @ref36; @ref37].

This is a descriptive study and therefore its principal limitation is that it cannot establish cause and effect linkages between arterial blockages, oxidative damage, myofiber type degeneration and PAD clinical manifestations. Instead, the study demonstrated that there is increased oxidative damage in association with degeneration of myofiber size and shape in PAD gastrocnemius, that the damage is selective for Type II myofibers and is worse in the most advanced stage of PAD. These findings are in agreement with prior work from our and other laboratories demonstrating that arterial blockages in the legs of PAD patients produce ischemia-induced oxidative stress and progressive accumulation of oxidative damage to all the tissues (including muscle, nerves, skin, and subcutaneous tissues) of the affected limb [@ref4; @ref7; @ref9; @ref10; @ref38; @ref39]. In the long-term, this accumulation of oxidative damage in the ischemic tissues leads to gradual decline of the PAD limb and may contribute to progression of the manifestations of the disease from claudication to critical limb ischemia and eventual limb loss. Our findings are also consistent with the type of functional disability we see in PAD patients. Specifically, in PAD muscles Type II fibers that are high, energy consumers and are designed for short explosive movements appear to be preferentially lost while Type I fibers that are energy conserving and are optimized for prolonged low-intensity (fatigue resistant) activities are less damaged and more represented in the PAD muscle [@ref40]. This selectivity may in part explain the fact that, compared to controls, PAD patients walk with reduced cadence, have decreased gait variability and decreased performance of the foot plantar flexors [@ref41; @ref42; @ref43]. In this study, we evaluated oxidative damage in different myofiber types as a correlate of myofiber degeneration and PAD disease progression. In the future, more detailed evaluation of the proteolytic pathways and signaling networks responsible for myofiber degeneration and their Type II selectivity can be also evaluated in muscle samples obtained from PAD patients. High quality human data are critical for improving our knowledge of the mechanisms operating to produce PAD myopathy and for the development of specific therapies with validated biomarkers of relevance to underlying mechanisms. Several therapies including exercise, nutritional therapy, medications that enhance mitochondrial function and antioxidant defenses, androgens, growth hormone, ghrelin and its mimetics, myostatin inhibitors and anti-inflammatory agents have been proposed for the management of acquired myopathies [@ref18; @ref19] and may be promising approaches to the management of PAD patients.

In summary, our work demonstrates that there is increased myofiber oxidative damage and degeneration in PAD gastrocnemius, that this damage is selective for Type II myofibers and is worse in the most advanced stage of PAD. These findings are consistent with myofiber oxidative damage as a significant contributor to the pathophysiology of PAD and provide insight into possible mechanisms behind the preferential damage of Type II myofibers and the chronic and progressive nature of PAD. Accumulating oxidative damage in the ischemic limb may cause the patient to transition from claudication to critical limb ischemia and eventually limb loss. In the future this type of work can help identify the mechanisms responsible for the myopathy of PAD and can lead to a better understanding of the pathogenesis of the disease and to the design of individualized and targeted interventions essential for much needed improvement of diagnosis, staging and treatment of patients suffering from PAD.
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![Myopathy in PAD limbs is easily demonstrated. Control skeletal muscle (A) and ischemic muscle from age- and sex-matched PAD patients with early (B) and late stage (C) disease were stained with Masson trichrome and images were captured under bright-field conditions with a 10× objective. Control muscle (A) exhibits polygonal myofibers of uniform shape and size and thin endomysium and perimysium. Myofiber shape and size are less uniform in early stage PAD muscle (B). The specimen includes large, swollen fibers, irregularly-shaped microfibers and thickened, collagenous endomysium and perimysium. Most myofibers of late stage muscle (C) are irregular in shape and size and include many large, rounded and swollen fibers and many small, irregularly shaped fibers. There is extensive replacement of myofibers with fibrous tissue. The black bars represent a length of 100 µm.](gr1){#f0005}

![Each muscle specimen was labeled for identification of nuclei (A, bright nodes along the sarcolemma), sarcolemma (A, white outlines), and Type I (C) and Type II (D) myosin heavy chain and for quantification of myofiber carbonyl content (B, gray). Sarcolemmal outlines of Type I (C, green outlines) and Type II (D, red outlines) fibers were superimposed on the carbonyl image (B), permitting quantification of mean carbonyl content (gray) for each myofiber type. Morphometrics were determined from the sarcolemmal images of each fiber type. The white bar represents a length of 100 microns.](gr2){#f0010}

![Representative images of gastrocnemius specimens are from a control subject (A and B) and a PAD patient (C and D) (10x). Each muscle specimen was labeled for quantification of carbonyl content (A and C, green) and for identification of nuclei (blue nodes along the sarcolemma), sarcolemma (blue outlines) and Type I (yellow, B and D), Type II (red, B and D) and Type I/II (orange, D) myosin heavy chains. PAD myofibers exhibited higher carbonyl content as indicated by the brighter, green signal (compare A and C), a larger proportion of Type I fibers (yellow, compare B and D) and smaller cross-sectional area (compare B and D). Hybrid fibers contained both Type I and Type II myosin heavy chain (orange, D). The white bars represent a length of 100 µm.](gr3){#f0015}

![Frequency of each fiber type in muscle from control subjects, PAD patients presenting with claudication (Fontaine stage II, PAD-II) and PAD patients presenting with critical limb ischemia (Fontaine stage IV, PAD-IV) is presented as percentage of all myofibers. The percentage of Type II fibers decreased while the percentage of Type I/II increased, as the disease progressed.](gr4){#f0020}

###### 

Baseline characteristics of PAD and control subjects.

                                        Control subjects   PAD patients                           
  ------------------------------------- ------------------ -------------- ----------- ----------- ---------
  **Number of subjects**                25                 53             28          25          \_
  **Mean** a**ge (years)**              62.7±2.1           64.7±1.0       62.6±1.7    67.0±1.6    0.340
  **Ankle brachial index**              1.08±0.02          0.40±0.04      0.53±0.04   0.25±0.04   \<0.001
  **Gender % (male/female)**            80/20              94.3/5.7       92.9/7.1    96/4        0.102
  **Smoking**                           28.00%             67.9%          67.90%      68.00%      0.001
  **Coronary** a**rtery** d**isease**   24.0%              45.3%          39.30%      52.00%      0.085
  **Obesity**                           44.0%              22.6%          17.90%      28.00%      0.066
  **Dyslipidemia**                      52.0%              64.2%          71.40%      56.00%      0.331
  **Type 1 diabetes mellitus**          32.0%              49.1%          32.10%      56.00%      0.222
  **Family** h**istory of PAD**         12.0%              15.1%          21.40%      8.00%       0.714
  **Hypertension**                      72.0%              77.4%          75.00%      80.00%      0.778

*Note*: Continuous variables are presented as mean±S.E.M.

*p* Values are for differences between control subjects and PAD patients "combined"; chi-square or Fisher's exact tests were used for categorical variables; independent *t* test was used for continuous variables.

###### 

Carbonyl content and morphometric parameters of PAD and control gastrocnemius myofibers.

                                   Control       PAD           \% Difference   *p*-value[⁎](#tbltbl2-fn1){ref-type="table-fn"}
  -------------------------------- ------------- ------------- --------------- -------------------------------------------------
  Type I                           1137±50       1424±33       ↑ 25            \<0.001
  Type II                          1175±49       1578±32       ↑ 34            \<0.001
  Type I/II                        1251±68       1601±43       ↑ 28            \<0.001
  Combined                         1216±47       1519±33       ↑ 25            \<0.001
                                                                               
  Cross-sectional area Type I      5748±316      4154±214      ↓ 28            \<0.001
  Cross-sectional area Type II     5692±331      3408±221      ↓ 40            \<0.001
  Cross-sectional area Type I/II   5550±381      3538±236      ↓ 36            \<0.001
  Combined                         5642±246      3700±176      ↓ 34            \<0.001
                                                                               
  Equivalent diameter Type I       153±5.4       134±3.6       ↓ 12            0.009
  Equivalent diameter Type II      150±6.1       117±4.1       ↓ 22            \<0.001
  Equivalent diameter Type I/II    151±6.8       121±4.0       ↓ 20            \<0.001
  Combined                         152±4.6       124±3.3       ↓ 20            \<0.001
                                                                               
  Perimeter Type I                 626±22        549±15        ↓ 12            0.009
  Perimeter Type II                632±24        500±16        ↓ 21            \<0.001
  Perimeter Type I/II              616±25        525±15        ↓ 15            0.004
  Combined                         626±21        524±12        ↓ 16            \<0.001
                                                                               
  Solidity Type I                  0.941±0.003   0.930±0.002   ↓ 1.2           0.009
  Solidity Type II                 0.935±0.006   0.902±0.004   ↓ 3.5           \<0.001
  Solidity Type I/II               0.892±0.009   0.863±0.006   ↓ 3.2           0.004
  Combined                         0.923±0.002   0.898±0.003   ↓ 2.7           \<0.001
                                                                               
  Roundness Type I                 0.630±0.008   0.632±0.005   ↑ 0.3           0.793
  Roundness Type II                0.632±0.011   0.597±.008    ↓ 5.5           0.015
  Roundness Type I/II              0.554±0.014   0.549±0.009   ↓ 0.9           0.756
  Combined                         0.609±0.007   0.592±0.006   ↓ 2.8           0.094

*p*-Values are adjusted for the effect of smoking status.

###### 

Carbonyl content and morphometric parameters in PAD-II and PAD-IV patients.

                                   PAD-II        PAD-IV        \% Difference   *p*-value[⁎](#tbltbl3-fn1){ref-type="table-fn"}
  -------------------------------- ------------- ------------- --------------- -------------------------------------------------
  Type I                           1329±41       1496±44       ↑ 12            0.009
  Type II                          1493±45       1643±48       ↑ 10            0.028
  Type I/II                        1483±57       1701±61       ↑ 15            0.012
  Combined                         1435±34       1613±53       ↑ 12            0.008
                                                                               
  Cross-sectional area Type I      4747±262      3497±277      ↓ 26            0.002
  Cross-sectional area Type II     4294±208      2519±252      ↓ 41            \<0.001
  Cross-sectional area Type I/II   4523±219      2453±232      ↓ 45            \<0.001
  Combined                         4521±162      2823±203      ↓ 38            \<0.001
                                                                               
  Equivalent diameter Type I       145 ±4.2      122±4.5       ↓ 15            \<0.001
  Equivalent diameter Type II      131±4.6       99±4.9        ↓ 24            \<0.001
  Equivalent diameter Type I/II    140±4.1       98±4.3        ↓ 30            \<0.001
  Combined                         139±3.1       107±3.9       ↓ 23            \<0.001
                                                                               
  Perimeter Type I                 586±16        506±17        ↓ 14            0.002
  Perimeter Type II                546±18        443±19        ↓ 19            \<0.001
  Perimeter Type I/II              605±15        437±15        ↓ 28            \<0.001
  Combined                         579±9.8       462±14        ↓ 20            \<0.001
                                                                               
  Solidity Type I                  0.938±0.003   0.921±0.003   ↓ 1.8           \<0.001
  Solidity Type II                 0.918±0.005   0.884±0.005   ↓ 3.7           \<0.001
  Solidity Type I/II               0.861±0.007   0.861±0.008   0               0.981
  Combined                         0.905±0.003   0.889±0.004   ↓ 1.8           0.003
                                                                               
  Roundness Type I                 0.645±0.007   0.619±0.007   ↓ 4.0           0.013
  Roundness Type II                0.624±0.009   0.564±0.010   ↓ 9.6           \<0.001
  Roundness Type I/II              0.552±0.011   0.544±0.011   ↓ 1.4           0.609
  Combined                         0.606±0.005   0.575±0.008   ↓ 5.1           0.004

*p*-Values are adjusted for the effect of smoking status.

[^1]: Co-first authors.

[^2]: Co-senior authors.
